Best Compounded GLP-1 Telehealth Providers of 2026
Compounded GLP-1s, semaglutide and tirzepatide mixed by 503A or 503B compounding pharmacies, remain the most affordable on-ramp to the GLP-1 category in 2026. The FDA's 2024 ruling closed the official tirzepatide shortage, which means compounding now operates under the personalisation exception (a clinician must document a clinical justification, such as dose customisation, the addition of B12, or a documented intolerance to an inactive ingredient in the brand-name product). Pricing, pharmacy licensure, and formulation breadth still vary widely between providers. We compared every clinic in our network that ships a compounded GLP-1, and ranked the ones with the strongest combination of pharmacy transparency, real clinical oversight, and price predictability.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
Compounded GLP-1s — semaglutide and tirzepatide prepared by 503A or 503B compounding pharmacies — became the dominant low-cost access pathway to GLP-1 therapy during the 2022–2025 drug shortage period. The FDA removed tirzepatide from the shortage list in October 2024 and has been phasing out compounding exemptions for semaglutide through 2025–2026. As of mid-2026, compounding is still legally available under the personalisation exception — a prescriber must document a clinical justification such as dose customisation, addition of B12, or a documented intolerance to an inactive ingredient in the brand-name product.
The quality gap between compounding providers is significant. The best providers use FDA-registered 503B outsourcing facilities with USP 797 sterility documentation and named pharmacy partners. The worst use unnamed 503A compounders with no public quality documentation. Pricing ranges from $80–$350/month depending on dose, provider, and whether the formulation includes add-ins like B12 or L-carnitine.
We compared every clinic in our network that ships a compounded GLP-1 and ranked the ones with the strongest combination of pharmacy transparency, real clinical oversight, and price predictability. Brand-name GLP-1 access was not weighted — this list is specifically about compounded quality.
The Ranking
WellMedr
A multi-category telehealth platform with compounded semaglutide shown from $49/mo and tirzepatide from $89/mo on 12-month plans, plus a 4.6/5 Trustpilot record.
Editor’s take: WellMedr is a value-led option for people who want compounded GLP-1 access plus the convenience of additional men's-health and hair-loss categories under one account. Its public Trustpilot profile displayed a 4.6/5 rating from 1,963 reviews when checked September 27, 2026. The current checkout showed semaglutide at $49/mo on a prepaid 12-month term and $99 month to month, while tirzepatide was $89/mo on a prepaid 12-month term and $129 month to month. Compounded medications are not FDA-approved finished drugs; confirm the exact prescription, pharmacy, dose progression, cancellation terms and total commitment with the clinician before paying.
Full review →
Hone Health
Hormone optimisation platform with real biomarker testing and physician-guided protocols, for men and women.
Editor’s take: If you take hormone health seriously and you're willing to pay for biomarker testing, Hone is the most clinically credible option in this list. If you only want low-friction TRT and you're price-sensitive, Peter MD or DudeMeds will fit better.
Full review →
SkinnyRx
Clinician-guided GLP-1 platform with both compounded and brand-name access plus overnight shipping.
Editor’s take: Premium positioning, premium catalog. If you want maximum optionality across GLP-1 modalities, this is the deepest menu on the site. The premium catalog comes at a premium price. If you want maximum optionality across GLP-1 modalities, SkinnyRx is the deepest menu on the site; if you want the lowest cost, look at Trimi or HealthRx.
Full review →
NewSelf
Industry-low flat-dose pricing on compounded semaglutide and tirzepatide — all dosages, one price, no membership fee.
Editor’s take: One of the most aggressively priced compounded GLP-1 clinics on the market. Flat-dose pricing is a genuine differentiator — you won't pay more as your dose increases. Customer service responsiveness has been flagged in some reviews; verify support quality before committing to a long-term plan.
Full review →
bmiMD
Plan-length-priced compounded semaglutide with optional longevity add-ons and online clinician access.
Editor’s take: The current semaglutide ladder is easy to compare when you separate the $129 month-to-month option from the lower long-term rates. Do not assume that price applies to tirzepatide, higher doses, or optional add-ons; verify the checkout total before committing.
Full review →
Eden
Flat upfront pricing with the same dose-equal cost across both compounded and brand-name GLP-1s.
Editor’s take: A genuinely buyer-friendly pricing model. Eden also has the deepest longevity menu of any GLP-1-led clinic on this list. methylene blue and GHK-Cu are not common.
Full review →
Yucca Health
Provider-guided care from US-licensed pharmacies, covering GLP-1, NAD+, and recovery-focused peptides.
Editor’s take: A solid recovery-and-longevity-leaning GLP-1 clinic. If you want a pure, lowest-cost compounded GLP-1, you can pay less elsewhere, but the recovery angle is genuinely differentiated. If you want a pure, lowest-cost compounded GLP-1 without the longevity framing, you can pay less elsewhere. The recovery and longevity add-ons are the main reason to choose Yucca Health over a cheaper GLP-1 specialist.
Full review →
Sesame Care
Cash-pay telehealth marketplace with transparent per-visit pricing and Costco-member discounts.
Editor’s take: A flat-fee marketplace that earns its place when you only need a single transparent visit. Sustained GLP-1 buyers may prefer a dedicated specialty clinic. If you want a sustained GLP-1 program with ongoing provider support, a dedicated GLP-1 clinic will offer better continuity than Sesame's per-visit marketplace model.
Full review →
Direct Meds
Compounded GLP-1 clinic with transparent pricing and dedicated nurse support.
Editor’s take: Direct Meds is easier to compare than a program that separates its membership fee from medication, provided the public $249 and $297 starting points match the treatment path you are offered. Skip it if you specifically want brand-name GLP-1 access or in-state pickup.
Full review →
Shed Rx
GLP-1 clinic offering injections, oral semaglutide, drops, and lozenges plus brand-name Wegovy and Zepbound.
Editor’s take: A reasonable mid-priced pick when delivery flexibility matters. Verify auto-billing terms before signing up given mixed reports. Verify auto-billing terms before signing up given mixed reviews on cancellation. If delivery flexibility is your priority, compare ShedRx against Breeze Meds which also offers sublingual tirzepatide.
Full review →Rugiet
Men's performance medicine platform with a proprietary 3-in-1 sublingual ED treatment (sildenafil + tadalafil + apomorphine), TRT, sleep Rx, and GLP-1 weight loss.
Editor’s take: The most differentiated ED product in the telehealth market. The 3-in-1 sublingual formula is genuinely novel, and the multi-category platform (TRT, sleep, GLP-1) makes Rugiet a strong single-provider option for men managing multiple health goals.
Full review →
Women-focused telehealth combining compounded GLP-1 weight loss with HRT support.
Editor’s take: A focused women's health pick. If you only want GLP-1, you'll find cheaper; if you want both GLP-1 and HRT in one clinic, this is one of the cleanest options on the list. If you only want GLP-1 without hormonal support, a lower-cost specialist like Trimi or HealthRx will be more cost-effective. If you want both GLP-1 and HRT in one clinic, Gala Health is one of the cleanest options available.
Full review →2026 Price Comparison. All-In Monthly Cost
Prices verified June 2026· How we verify →Published monthly price terms at the lowest listed rate and higher listed rate. Read each provider’s terms note because medication, consult, shipping, and plan-length conditions vary.
Prices are verified from public provider websites and may change. Compounded medications are from 503A pharmacies operating under personalisation exceptions. Always confirm pricing and legal status directly with the provider before purchase.
| Provider | Starting dose | Maintenance dose | Pharmacy | Trustpilot | Verified | Actions |
|---|---|---|---|---|---|---|
Semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month. | $49/mo | $99 – $129/mo | 503A | 4.6 | Aug 11 | |
First-month pricing on longer plans | $49/mo | $199/mo | 503A | 4.9 | Jul 13 | |
TrimiLowest Flat Rate Flat rate at every dose | $99/mo | $125/mo | 503A | 4.7 | June 2026 | |
| $149/mo | $249/mo | 503A | 4.8 | June 2026 | ||
Includes coaching | $198/mo | $299/mo | 503A | 4.7 | June 2026 | |
| $199/mo | $299/mo | 503A | 4.7 | June 2026 |
Semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
- Starting dose
- $49/mo
- Maintenance dose
- $99 – $129/mo
- Pharmacy
- 503A
- Price checked
- Aug 11
First-month pricing on longer plans
- Starting dose
- $49/mo
- Maintenance dose
- $199/mo
- Pharmacy
- 503A
- Price checked
- Jul 13
- Starting dose
- $99/mo
- Maintenance dose
- $125/mo
- Pharmacy
- 503A
- Price checked
- June 2026
- Starting dose
- $149/mo
- Maintenance dose
- $249/mo
- Pharmacy
- 503A
- Price checked
- June 2026
Includes coaching
- Starting dose
- $198/mo
- Maintenance dose
- $299/mo
- Pharmacy
- 503A
- Price checked
- June 2026
- Starting dose
- $199/mo
- Maintenance dose
- $299/mo
- Pharmacy
- 503A
- Price checked
- June 2026
All prices are all-in (consult + medication + shipping) unless noted. Prices verified June 2026. Compounded medications are not FDA-approved finished products. They are compounded under 503A personalisation exceptions. Click any provider name to read the full independent review. CTA buttons link to provider websites and may earn us a commission. How we verify prices →
Methodology
Each provider was scored on four axes: (1) compounded formulary breadth (injectable, oral, sublingual, lozenge, microdose), (2) price-per-mg transparency at every dose tier, (3) pharmacy disclosure (503A vs 503B, named partner, USP-797 sterility documentation), and (4) clinical oversight depth (real video visits vs async-only, prescriber state coverage, follow-up cadence). Brand-name access was not weighted, this list is specifically about compounded GLP-1 quality, not Wegovy or Zepbound availability.
Compounded GLP-1: The Regulatory Landscape and What It Means for You
Compounded semaglutide and tirzepatide have been the dominant form of GLP-1 telehealth for the past two years. The regulatory situation is shifting, and patients starting a compounded protocol today are taking on more uncertainty than patients who started in 2023. Here is what you need to understand.
The Shortage List and Why It Matters
Under section 503A of the FD&C Act, traditional compounding pharmacies can prepare copies of FDA-approved drugs only when those drugs appear on the FDA's drug-shortage list. Semaglutide and tirzepatide were added to the shortage list in 2022 and 2023 respectively, which is what made the compounded GLP-1 telehealth market possible at scale.
The FDA has been removing these drugs from the shortage list as supply normalizes. Once a drug is removed, the 503A pathway for compounded copies narrows significantly — compounding is still permitted for individual patient needs (specific allergies, dosing requirements) but not for general commercial distribution. This means the compounded GLP-1 you start today may not be available in the same form in 6–12 months.
503A vs 503B: Why the Pharmacy Type Matters
503A pharmacies are traditional compounding pharmacies that prepare medications for individual patients based on a prescription. They are not FDA-registered and are not subject to FDA manufacturing inspections. 503B outsourcing facilities are FDA-registered, subject to cGMP manufacturing standards, and can produce larger batches for distribution to healthcare providers.
For patients, the practical difference is quality assurance. 503B facilities have demonstrated manufacturing controls; 503A facilities have not been independently verified. The FDA has issued warning letters to multiple 503A pharmacies for contamination, mislabeling, and potency issues with compounded semaglutide. Clinics that use 503B-sourced compounded GLP-1s are operating at a higher quality bar.
What to Ask Before Signing Up
Before starting a compounded GLP-1 protocol, ask the clinic: Is the medication sourced from a 503A or 503B pharmacy? What is the pharmacy's name? Does the formulation include any additives (B12, L-carnitine, etc.) and if so, why? What is the clinic's contingency plan if the shortage list status changes?
Clinics that cannot or will not answer these questions clearly are not operating with the transparency that a long-term medication protocol requires.
Compounded GLP-1 therapy is a legitimate option for patients who cannot access or afford brand-name Wegovy or Zepbound — but it comes with regulatory uncertainty that brand-name therapy does not. The clinics in our top tier above are transparent about their pharmacy sourcing and have contingency plans for regulatory changes.
What the Studies Actually Show
Compounded GLP-1s contain the same active ingredient as Wegovy / Ozempic (semaglutide) or Zepbound / Mounjaro (tirzepatide). They have not themselves been studied in randomised trials; efficacy is inferred from the trials of the underlying API, summarised below.
| Endpoint | Finding |
|---|---|
| Mean weight loss (STEP 1, 68 weeks, 2.4 mg)1 | −14.9% body weight vs −2.4% placebo in adults with overweight/obesity without diabetes |
| Cardiovascular outcomes (SELECT, ~40 months)2 | 20% relative risk reduction in major adverse cardiovascular events (MACE) in adults with established CV disease and overweight/obesity |
| GI side effects (FDA prescribing information)3 | Nausea ≥10%, diarrhea ≥10%, vomiting ≥10%, constipation ≥10%; most cases mild–moderate and dose-dependent |
| Boxed warning3 | Risk of thyroid C-cell tumors observed in rodent studies; contraindicated in personal/family history of MTC or MEN 2 |
| Mean weight loss (SURMOUNT-1, 72 weeks, 15 mg)6 | −20.9% body weight vs −3.1% placebo in adults with obesity without diabetes |
| Mean weight loss with T2D (SURMOUNT-2, 72 weeks, 15 mg)7 | −14.7% body weight in adults with type 2 diabetes |
| Sleep apnea (SURMOUNT-OSA)8 | Tirzepatide reduced apnea-hypopnea index (AHI) by ~25–29 events/hour vs placebo at 52 weeks; FDA-approved labeling for moderate-to-severe OSA in obesity |
Frequently Asked Questions
- STEP 1 — NEJM 2021 · Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
- SELECT — NEJM 2023 · Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221–2232.
- FDA Prescribing Information — Wegovy (semaglutide) · WEGOVY (semaglutide) injection, for subcutaneous use. U.S. Food and Drug Administration prescribing information.
- SUSTAIN program — ADA scientific summary · Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 clinical trials. Diabetes Obes Metab 2019;21(7):1601–1613.
- FDA — Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (last updated 2024).
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SURMOUNT-2 — Lancet 2023 · Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613–626.
- SURMOUNT-OSA — NEJM 2024 · Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193–1205.
- FDA Prescribing Information — Zepbound (tirzepatide) · ZEPBOUND (tirzepatide) injection, for subcutaneous use. U.S. Food and Drug Administration prescribing information.
- SURPASS — program summary · Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.
- FDA — Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (last updated 2024).
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.
Compare Top Providers
- bmiMD vs SkinnyRx (2026): Which Compounded GLP-1 Clinic Wins?
- bmiMD vs Direct Meds (2026): Compounded GLP-1 Clinic Comparison
- SkinnyRx vs Shed Rx (2026): Which GLP-1 Clinic Is Right for You?
- Tonik vs bmiMD (2026): Full-Stack Clinic vs Low-Cost Entry
- bmiMD vs FuturHealth (2026): Compounded GLP-1 Clinic Comparison
- TrimRx vs SkinnyRx (2026): Brand-Name Access vs Oral GLP-1 Options
- Shed Rx vs bmiMD (2026): Which Budget GLP-1 Clinic Wins?
- Breeze Meds vs bmiMD (2026): Sublingual GLP-1 vs Standard Injectable
- FuturHealth vs SkinnyRx (2026): Coaching-First vs Oral GLP-1 Specialist